| [1] |
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013, 13(4): 227-242.
doi: 10.1038/nri3405
URL
|
| [2] |
Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma[J]. J Dtsch Dermatol Ges, 2011, 9(4): 277-286.
|
| [3] |
Zhai Y, Moosavi R, Chen M. Immune checkpoints, a novel class of therapeutic targets for autoimmune diseases[J]. Front Immunol, 2021, 12: 645699.
doi: 10.3389/fimmu.2021.645699
URL
|
| [4] |
Xiang Z, Zhou Z, Song S, et al. Dexamethasone suppresses immune evasion by inducing GR/STAT 3 mediated downregulation of PD-L1 and IDO1 pathways[J]. Oncogene, 2021, 40(31): 5002-5012.
doi: 10.1038/s41388-021-01897-0
pmid: 34175886
|
| [5] |
Zahavi DJ, Weiner LM. Targeting multiple receptors to increase checkpoint blockade efficacy[J]. Int J Mol Sci, 2019, 20(1): 158.
doi: 10.3390/ijms20010158
URL
|
| [6] |
Hernández áP, Juanes-Velasco P, Landeira-Viñuela A, et al. Restoring the immunity in the tumor microenvironment: insights into immunogenic cell death in onco-therapies[J]. Cancers (Basel), 2021, 13(11): 2821.
doi: 10.3390/cancers13112821
URL
|
| [7] |
Muller AJ, Manfredi MG, Zakharia Y, et al. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond[J]. Semin Immunopathol, 2019, 41(1): 41-48.
doi: 10.1007/s00281-018-0702-0
URL
|
| [8] |
Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy[J]. Nat Med, 2019, 25(4): 656-666.
doi: 10.1038/s41591-019-0374-x
pmid: 30833750
|
| [9] |
Ren X. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle[J]. Cancer Biol Med, 2019, 16(2): 205-210.
doi: 10.20892/j.issn.2095-3941.2018.0141
URL
|
| [10] |
Mathieu L, Shah S, Pai-Scherf L, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer[J]. Oncologist, 2021, 26(5): 433-438.
doi: 10.1002/onco.13752
URL
|
| [11] |
Kaplon H, Reichert JM. Antibodies to watch in 2019[J]. MAbs, 2019, 11(2): 219-238.
doi: 10.1080/19420862.2018.1556465
URL
|
| [12] |
Keam SJ. Toripalimab: first global approval[J]. Drugs, 2019, 79(5): 573-578.
doi: 10.1007/s40265-019-01076-2
URL
|
| [13] |
Zhang Y, Li X, Sun Y, et al. Pharmacokinetics of S-epacadostat, an indoleamine 2,3-dioxygenase 1 inhibitor, in dog plasma and identification of its metabolites in vivo and in vitro[J]. Biomed Chromatogr, 2021, 35(12); e5226.
doi: 10.1002/bmc.5226
pmid: 34388261
|
| [14] |
Shi JG, Bowman KJ, Chen X, et al. Population pharmacokinetic and pharmacodynamic modeling of epacadostat in patients with advanced solid malignancies[J]. J Clin Pharmacol, 2017, 57(6): 720-729.
doi: 10.1002/jcph.855
URL
|
| [15] |
Yu Y. Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers[J]. Cancer Biol Med, 2021, 18 (4): 944-948.
doi: 10.20892/j.issn.2095-3941.2021.0491
URL
|
| [16] |
Fattakhova E, Hofer J, DiFlumeri J, et al. Identification of the FDA-approved drug pyrvinium as a small-molecule inhibitor of the PD-1/PD-L1 interaction[J]. ChemMedChem, 2021, 16(18): 2769-2774.
doi: 10.1002/cmdc.202100264
URL
|
| [17] |
Han N, Hwang W, Tzelepis K, et al. Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies[J]. Sci Adv, 2021, 7(27): eabh3032.
doi: 10.1126/sciadv.abh3032
URL
|
| [18] |
Bronte G, Verlicchi A, De Matteis S, et al. Circulating myeloid-derived suppressive-like cells and exhausted immune cells in non-small cell lung cancer patients treated with three immune checkpoint inhibitors[J]. Front Immunol, 2021, 12: 672219.
doi: 10.3389/fimmu.2021.672219
URL
|
| [19] |
Takahashi A, Namikawa K, Ogata D, et al. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma[J]. J Dermatol, 2020, 47(11): 1267-1275.
doi: 10.1111/1346-8138.15521
URL
|
| [20] |
Gaudreau PO, Lee JJ, Heymach JV, et al. Phase Ⅰ/Ⅱ trial of immunotherapy with durvalumab and tremelimumab with continuous or intermittent MEK inhibitor selumetinib in NSCLC[J]. Clin Lung Cancer, 2020, 21(4): 384-388.
doi: 10.1016/j.cllc.2020.02.019
URL
|
| [21] |
Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma[J]. J Clin Oncol, 2017, 35(34): 3851-3858.
doi: 10.1200/JCO.2016.72.1985
pmid: 28678668
|
| [22] |
McGregor BA, Campbell MT, Xie W, et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies[J]. Cancer, 2021, 127(6): 840-849.
doi: 10.1002/cncr.33328
URL
|
| [23] |
Ebata T, Shimizu T, Fujiwara Y, et al. Phase Ⅰ study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours[J]. Invest New Drugs, 2020, 38(2): 468-477.
doi: 10.1007/s10637-019-00787-3
URL
|
| [24] |
Jung KH, LoRusso P, Burris H, et al. Phase Ⅰ study of the indoleamine 2,3-dioxygenase 1(IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors[J]. Clin Cancer Res, 2019, 25: 3220-3228.
doi: 10.1158/1078-0432.CCR-18-2740
URL
|
| [25] |
Hollebecque A, Chung HC, de Miguel MJ, et al. Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors[J]. Clin Cancer Res, 2021, 27(23): 6393-6404.
doi: 10.1158/1078-0432.CCR-21-0261
pmid: 34465599
|
| [26] |
Atkinson V, Khattak A, Haydon A, et al. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma[J]. J Immunother Cancer, 2020, 8(2): e001681.
doi: 10.1136/jitc-2020-001681
URL
|
| [27] |
De Luca AJ, Lyons AB, Flies AS. Cytokines: signalling improved immunotherapy?[J]. Curr Oncol Rep, 2021, 23(9): 103.
doi: 10.1007/s11912-021-01095-x
URL
|
| [28] |
Shibata Y, Murakami S, Kato T. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors[J]. Expert Opin Drug Saf, 2021, 20(5): 537-547.
doi: 10.1080/14740338.2021.1898584
URL
|
| [29] |
Cunningham M, Iafolla M, Kanjanapan Y, et al. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy[J]. PLoS One, 2021, 16(6): e0253070.
doi: 10.1371/journal.pone.0253070
URL
|
